Successful rituximab treatment of granulomatosis with polyangiitis with cranial neuropathies
نویسندگان
چکیده
منابع مشابه
Rituximab in the treatment of eosinophilic granulomatosis with polyangiitis.
BACKGROUND The general consensus is that for patients with EGPA with poor prognosis, intensive therapy with both GC and CF is indicated. The maintenance of remission is made with GC and AZA. A considerable number of patients with EGPA are refractory to first line therapy, experience dose-limiting side effects or relapse. In clinical trials, RTX was effective for the treatment of ANCA-associated...
متن کاملPlace in therapy of rituximab in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis
Granulomatosis with polyangiitis and microscopic polyangiitis are small vessel vasculitides characterized by circulating antineutrophil circulating antibodies. Standard treatment for active severe disease has consisted of cyclophosphamide with glucocorticoids with or without plasmapheresis, which achieves approximately 75% sustained remission, but carries significant adverse effects such as mal...
متن کاملAn Unusual Presentation of Granulomatosis with Polyangiitis
The granulomatosis with polyangiitis (GPA), formerly known as Wegener’s granulomatosis, is a pauci-immune vasculitis involving small- and medium-sized blood vessels. Classically, the patients inflicted with this disease present with a triad of necrotizing granulomatous inflammation of the respiratory tract, cutaneous necrotizing vasculitis, and glomerulonephritis (GN). The antinuclear (ANA) and...
متن کاملSuccessful Treatment of ANCA-Negative Wegener's Granulomatosis with Rituximab
Wegener's Granulomatosis (WG) is a systemic vasculitis typically associated with antineutrophil cytoplasmic antibodies (ANCAs). A small proportion of patients are ANCA negative, however, and this is more commonly found in individuals with disease limited to the ears, nose, throat, and lungs, who do not have renal involvement. Rituximab is a monoclonal anti-CD20 antibody that has been demonstrat...
متن کاملOtolaryngological progression of granulomatosis with polyangiitis after systemic treatment with rituximab.
OBJECTIVE Rituximab is used for the treatment of granulomatosis with polyangiitis (GPA), historically known as Wegener's granulomatosis. However, the otolaryngological progression of GPA after systemic treatment with rituximab (Rituxan) is unclear. We therefore examined the disease sequelae of patients with GPA who were treated with rituximab. STUDY DESIGN Case series with chart review. SET...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Inflammation and Regeneration
سال: 2018
ISSN: 1880-8190
DOI: 10.1186/s41232-018-0079-4